5篇
您的检索式：作者名="Heidi Andersen"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Contact allergy to common ingredients in hair dyes显示文摘 | Heidi S?sted Thomas Rustemeyer Margarida Gon?alo Magnus Bruze An Goossens Ana M. Giménez‐Arnau Christophe J. Le Coz Ian R. White Thomas L. Diepgen Klaus E. Andersen Tove Agner Howard Maibach Torkil Menné Jeanne D. Johansen | 2013 | Contact Dermatitis2013，，1： | 1 |
| 2 | Processes of Care and Medical Complications in Patients With Stroke显示文摘 | Annette Ingeman Grethe Andersen Heidi H.Hundborg Marie L.Svendsen Soren P.Johnsen | | 0，，： | 1 |
| 3 | The ear skin temperature as an indicator of the thermal comfort of pigs 显示文摘 | Heidi Mai-Lis Andersen Erik Jcrgensen Lise Dybkjae | 2008 | Applied Animal Behaviour Science2008，113，12： | 1 |
| 4 | Tissue distribution and clearance of tritium-labeled dihydromicrocystin-LR epimers administered to Atlantic salmon via intraperitoneal injection显示文摘 | David E Williams Michael L Kent Raymond J Andersen Heidi Klix Charles F.B Holmes | 1995 | Toxicon1995，，2： | 1 |
| 5 | Current challenges in applying gene-driven therapies in clinical lung cancer practice显示文摘Over the last twenty years,with the development of gene-driven therapies,numerous new drugs have entered clinical use.Very few of these new drugs are suitable for a large number of patients,and all require molecular genetic testing.In lung cancer,gene-targeted therapy has evolved rapidly and has placed demands on the development of diagnostics and tissue sample preparation and logistics.Rapid diagnosis and prevalence assessment are necessary to determine the prognosis of a lung cancer patient based on the latest research findings.Therefore,the molecular-genetic diagnostic pathway must also be accelerated and matured to do the necessary analyses on small samples.Because lung cancer rebiopsy can be difficult,liquid biopsy techniques should be developed to cover more of the treatable mutations.There are obstacles related to tissue sampling,new genomic techniques and access to gene-driven cancer drugs,including their affordability.With this review and case study,we go into the obstacles faced by our clinic and discuss how to tackle these obstacles in lung cancer.We use lung cancer as an example due to its complexity,though these same obstacles are found in different cancers on a minor scale. | Jatta Saarenheimo Heidi Andersen Natalja Eigeliene Antti P Jekunen | 2021 | World Journal of Clinical Oncology2021，12，8： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员